% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hofmann:272980,
      author       = {Hofmann, Anna and Häsler, Lisa M and Lambert, Marius and
                      Kaeser, Stephan and Gräber-Sultan, Susanne and Obermüller,
                      Ulrike and Kuder-Buletta, Elke and la Fougère, Christian
                      and Laske, Christoph and Vöglein, Jonathan and Levin,
                      Johannes and Fox, Nick C and Ryan, Natalie S and Zetterberg,
                      Henrik and Llibre-Guerra, Jorge J and Perrin, Richard J and
                      Ibanez, Laura and Schofield, Peter R and Brooks, William S
                      and Day, Gregory S and Farlow, Martin R and Allegri, Ricardo
                      F and Chrem Mendez, Patricio and Ikeuchi, Takeshi and
                      Kasuga, Kensaku and Lee, Jae-Hong and Roh, Jee Hoon and
                      Mori, Hiroshi and Lopera, Francisco and Bateman, Randall J
                      and McDade, Eric and Gordon, Brian A and Chhatwal, Jasmeer P
                      and Jucker, Mathias and Schultz, Stephanie A},
      collaboration = {Network, Dominantly Inherited Alzheimer},
      othercontributors = {Aguillon, David and Aschenbrenner, Andrew J and Baker,
                          Bryce and Barthelemy, Nicolas and Bateman, Randall and
                          Bechara, Jacob A and Benzinger, Tammie and Berman, Sarah B
                          and Cash, David M and Chen, Allison and Chen, Charles and
                          Chhatwal Chhatwal, Jasmeer P and Mendez, Patricio Chrem and
                          Courtney, Laura and Cruchaga, Carlos and Daniels, Alisha J
                          and Day, Gregory S and Fagan, Anne M and Farlow, Martin and
                          Flores, Shaney and Franklin, Erin and Goate, Alison M and
                          Gräber-Sultan, Susanne and Graff-Radford, Neill R and
                          Gremminger, Emily and Hassenstab, Jason and Herries,
                          Elizabeth and Holtzman, David M and Hornbeck, Russ and Huey,
                          Edward D and Ikonomovic, Snezana and Jackson, Kelley and
                          Jarman, Steve and Jerome, Gina and Johnson, Erik C B and
                          Joseph-Mathurin, Nelly and Karch, Celeste M and Keefe, Sarah
                          and Koudelis, Deborah and Laske, Christoph and Leon, Yudy
                          Milena and Levey, Allan I and Li, Yan and Lu, Ruijin and
                          Marsh, Jacob and Martins, Ralph and Massoumzadeh, Parinaz
                          and Masters, Colin and McCullough, Austin and McDade, Eric
                          and McKay, Nicole and Minton, Matthew and Morris, John C and
                          Nadkarni, Neelesh K and Nicklaus, Joyce and Niimi, Yoshiki
                          and Noble, James M and Obermueller, Ulrike and Picarello,
                          Danielle M and Pulizos, Christine and Ramirez, Laura and
                          Renton, Alan E and Ringman, John and Rizzo, Jacqueline and
                          Rödenbeck, Yvonne Esther and Rosa-Neto, Pedro and
                          Sabaredzovic, Edita and Salloway, Stephen and Sanchez-Valle,
                          Raquel and Scott, Jalen and Seyfried, Nicholas T and
                          Simmons, Ashlee and Smith, Jennifer and Smith, Hunter and
                          Stauber, Jennifer and Stout, Sarah and Supnet-Bell, Charlene
                          and Surace, Ezequiel and Vazquez, Silvia and Vöglein,
                          Jonathan and Wang, Guoqiao and Wang, Qing and Xiong, Chengie
                          and Xu, Xiong and Xu, Jinbin},
      title        = {{C}omparative neurofilament light chain trajectories in
                      {CSF} and plasma in autosomal dominant {A}lzheimer's
                      disease.},
      journal      = {Nature Communications},
      volume       = {15},
      number       = {1},
      issn         = {2041-1723},
      address      = {[London]},
      publisher    = {Nature Publishing Group UK},
      reportid     = {DZNE-2024-01359},
      pages        = {9982},
      year         = {2024},
      abstract     = {Disease-modifying therapies for Alzheimer's disease (AD)
                      are likely to be most beneficial when initiated in the
                      presymptomatic phase. To track the benefit of such
                      interventions, fluid biomarkers are of great importance,
                      with neurofilament light chain protein (NfL) showing promise
                      for monitoring neurodegeneration and predicting cognitive
                      outcomes. Here, we update and complement previous findings
                      from the Dominantly Inherited Alzheimer Network
                      Observational Study by using matched cross-sectional and
                      longitudinal cerebrospinal fluid (CSF) and plasma samples
                      from 567 individuals, allowing timely comparative analyses
                      of CSF and blood trajectories across the entire disease
                      spectrum. CSF and plasma trajectories were similar at
                      presymptomatic stages, discriminating mutation carriers from
                      non-carrier controls 10-20 years before the estimated onset
                      of clinical symptoms, depending on the statistical model
                      used. However, after symptom onset the rate of change in CSF
                      NfL continued to increase steadily, whereas the rate of
                      change in plasma NfL leveled off. Both plasma and CSF NfL
                      changes were associated with grey-matter atrophy, but not
                      with Aβ-PET changes, supporting a temporal decoupling of
                      Aβ deposition and neurodegeneration. These observations
                      support NfL in both CSF and blood as an early marker of
                      neurodegeneration but suggest that NfL measured in the CSF
                      may be better suited for monitoring clinical trial outcomes
                      in symptomatic AD patients.},
      keywords     = {Humans / Alzheimer Disease: cerebrospinal fluid / Alzheimer
                      Disease: blood / Alzheimer Disease: genetics / Alzheimer
                      Disease: diagnosis / Neurofilament Proteins: blood /
                      Neurofilament Proteins: cerebrospinal fluid / Male / Female
                      / Biomarkers: cerebrospinal fluid / Biomarkers: blood /
                      Middle Aged / Cross-Sectional Studies / Adult / Longitudinal
                      Studies / Amyloid beta-Peptides: cerebrospinal fluid /
                      Amyloid beta-Peptides: blood / Atrophy / Gray Matter:
                      pathology / Gray Matter: diagnostic imaging / Aged /
                      Positron-Emission Tomography / Disease Progression /
                      Neurofilament Proteins (NLM Chemicals) / Biomarkers (NLM
                      Chemicals) / neurofilament protein L (NLM Chemicals) /
                      Amyloid beta-Peptides (NLM Chemicals)},
      cin          = {AG Jucker / AG Gasser / Clinical Research (Munich)},
      ddc          = {500},
      cid          = {I:(DE-2719)1210001 / I:(DE-2719)1210000 /
                      I:(DE-2719)1111015},
      pnm          = {352 - Disease Mechanisms (POF4-352) / 353 - Clinical and
                      Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-352 / G:(DE-HGF)POF4-353},
      experiment   = {EXP:(DE-2719)DIAN-20090101},
      typ          = {PUB:(DE-HGF)16},
      pmc          = {pmc:PMC11574007},
      pubmed       = {pmid:39557867},
      doi          = {10.1038/s41467-024-52937-8},
      url          = {https://pub.dzne.de/record/272980},
}